Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

Sermorelin cycle length: what human studies ran

Not approved — research use onlyBLimited human data
Short answer: there is no established Sermorelin cycle length, and we found no human studies that report one.

Treatment and follow-up in human studies

No human study durations are recorded.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • Sermorelin combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established Sermorelin cycle length?
No. We found no human studies that report a treatment duration for Sermorelin.
What is the longest human study of Sermorelin?
None is recorded.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
Sermorelin dosing reference Full research page

References

  1. Determination That GEREF (Sermorelin Acetate) Injection, 0.5 Milligrams Base/Vial and 1.0 Milligrams Base/Vial, and GEREF (Sermorelin Acetate) Injection, 0.05 Milligrams Base/Amp, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness (78 FR 14095) Federal Register (FDA notice). 2013
  2. Drugs@FDA application records for GEREF (NDA 019863 and NDA 020443), marketing status Discontinued, queried through openFDA openFDA / Drugs@FDA. 2026
  3. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency BioDrugs. 1999
  4. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy (Geref International Study Group) J Clin Endocrinol Metab. 1996
  5. EGRIFTA WR (tesamorelin) for injection, prescribing information (growth hormone-releasing factor physiology) FDA label (DailyMed). 2025
  6. World Anti-Doping Agency International Standard Prohibited List 2026 WADA. 2026
  7. PubChem compound record for sermorelin PubChem. 2026